We have completed enrollment in this study evaluating the effectiveness of body contouring devices. Dr. Cox is serving as the principal investigator.
We have completed enrollment for this study evaluating the effectiveness of a neuromodulator when used in the glabellar (betweeen the brows) area. Dr. Cox is serving as the principal investigator.
We are currently enrolling in this study evaluating augmentation of fullness in the jawline. Dr. Cox is serving as the principal investigator.
Dr. Cox completed work as the principal investigator on this multicenter, single-blind, randomized, controlled study of the safety and effectiveness of JUVÉDERM
VOLUMA® XC injectable gel for cheek augmentation using a cannula. Dr. Cox has long been an advocate for the safety and effectiveness of injecting with the use of a cannula rather than just a needle in the mid-face. This study began in February of 2018 and finished in October of 2018.
We have completed enrollment for this dermal filler study treating hollowing under the eyes (infraorbital hollowing). Dr. Cox is serving as principal investigator, and excited about the beautiful results we’re seeing with this new filler.
We have completed enrollment in this study evaluating augmentation of soft tissue fullness in the lips. Dr. Cox is serving as the principal investigator.
We have completed enrollment in a new study of an existing neuromodulator. The study is evaluating tweaks in the treatment of moderate to severe glabellar lines (those vertical lines between the brow). Dr. Cox is serving as the principal investigator.
Dr. Cox is currently serving as principal investigator in this follow-up to a recently completed study. The follow-up “An Open Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of [product] for Injection for Treatment of Moderate to Severe Glabellar Lines” is an unblinded study with multiple treatments. This new, Botox-like product is seeking registration for treatment of vertical lines between the eyebrows, and may eventually be the sixth injectable used to treat facial wrinkles and lines. Each will be unique in some way, patients working with skilled injectors will benefit from the ability to match product characteristics to individual anatomy. It’s an interesting time in aesthetic medicine! This study started in June 2017 and is in progress.
Dr. Cox recently completed work as principal investigator for the study “A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of [product] for Injection to Treat Moderate to Severe Glabellar Lines” This is another new, Botox-like product seeking registration for treatment of vertical lines between the eyebrows. This is the third new product in as many years looking to displace market leader Botox in the treatment of facial lines. Adding already registered Dysport and Xeomin to the mix means we’ll eventually have six (or more) injectables for treating facial lines. Each of the products is unique in some way, and we’ve really enjoyed working with the manufacturers to identify which patients will most benefit from the characteristics of their product. It’s an interesting time in aesthetic medicine! This study began in November 2016 and just finished in December 2017.
Dr. Cox is serving as principal investigator in the study “Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of [product] in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study.” This study is evaluating a new Botox-like product for treatment of vertical lines between the eyebrows. We expect this will come to market in the next year or so. As companies develop similar products with slightly different characteristics, there’s opportunity for skilled injectors to tailor treatments by selecting products best matched to an individual’s unique facial anatomy. It’s customized aesthetic medicine and we’re excited about the possibilities. The study began in October 2016 and is nearing completion.